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METHODS
We studied two national cohorts that included children with documented H1N1pdm09 infection, admitted to a pediatric intensive care unit (PICU) in Canada and in France between October 1, 2009 and January 31, 2010.
RESULTS
Vaccination coverage prior to admission to PICUs was higher in Canada than in France (21% vs 2% of children respectively, P < 0.001), and in both countries, vaccination coverage prior to admission of these critically ill patients was substantially lower than in the general pediatric population (P < 0.001). In Canada, 160 children (incidence = 2.6/100000 children) were hospitalized in PICU compared to 125 children (incidence = 1.1/100000) in France (P < 0.001). Mortality rates were similar in Canada and France (4.4% vs 6 .5%, P = 0.45, respectively), median invasive mechanical ventilation duration and mean PICU length of stay were shorter in Canada (4 d vs 6 
CONCLUSION
The critical illness due to H1N1pdm09 had a higher incidence in Canada than in France. Critically ill children were less likely to have received vaccination prior to hospitalization in comparison to general population and children vaccinated had lower risk of ventilation.
INTRODUCTION
By March 2009, pandemic influenza A(H1N1)pdm09 had begun to spread from Mexico across the globe. The epidemiology of the first pandemic wave in Canada revealed that A(H1N1)pdm09 affected both young healthy patients and patients with underlying conditions. The severity of illness among children was high, pre dominantly due to severe hypoxic respiratory failure, resulting in prolonged pediatric intensive care unit (PICU) length of stay and mechanical ventilation, in comparison with seasonal influenza [1] . Countries from the Southern Hemisphere also reported early patterns of severity of illness including higher mechanical ventilation rate and higher mortality than previously observed with seasonal influenza [2, 3] .
To limit the impact of the pandemic influenza A(H1N1) pdm09 especially on children [46] , a vaccination campaign was conducted just before the second wave. However, different vaccine coverage across countries was observed, especially between Canada and France [710] . In order to study the impact of pandemic influenza H1N1 vaccination prior to hospitalization on critical illness, we conducted a binational observational study in 42 centers across Canada and France on pandemic influenza A(H1N1) associated critically illness in children, the most sensitive population affected by the pandemic. We originally hypothesized that the higher rate of vaccination coverage in children in Canada and previous exposure to influenza A(H1N1)pdm09 would have protected Canadian children from critical illness in the Fall of 2009.
MATERIALS AND METHODS
Ethical considerations
The participating institutions' research ethics boards approved study procedures in the two countries (Sainte Justine IRB and Bordeaux IRB). The need for informed consent was waived given the noninterventional study design.
Study design
We studied pandemic influenza A(H1N1)pdm09 incidence and severity in children in Canada and France using two multicenter national databases designed for pandemic surveillance. A key difference between the two countries was that 54% of children in Canada and 18% in France had been vaccinated [710] . On the other hand, Canada and France are two similar industrialized countries with a gross domestic product par capital ranking, 15 th and 23 rd rank in the world, respectively with similar per capita health expenditures [11, 12] . Their climates during autumn are similar (average temperatures (low/high) are 0 ℃ to 15 ℃ in Canada and 5 ℃ to 20 ℃ in France). France and Canada have similar health care systems in that they are based on social health insurance to provide near universal coverage to the adult and pediatric populations. Family practitioners provide primary health care in each country and most vaccine delivery does not require out ofpocket payment. The number of PICU is also similar (2.9 bed/100000 children under 15 years in Canada and 2.5 beds per 100000 children in France) [9, 13] . During the pandemic, treatment recommendations were the same, those of the World Health Organization. Although oseltamivir was not prescribed initially to children under two years of age in Canada, and under one year of age in France, as of October 27, 2009 in Canada and December 10, 2009 in France, these restrictions were abolished [14, 15] . Vaccination campaigns were organized in the two countries with the same priority groups and guidelines [1618] . The campaigns started on October 18, 2009 in Canada and October 20, 2009 in France [19] . Data collection was prospective in all Canadian PICUs (n = 17). In France, data collection was both pro spective and retrospective in 25 of 29 French PICUs. Four French PICUs did not participate to the study. All children admitted to a participating PICU in Canada and France, with documented A(H1N1)pdm09 infection between October 1 2009 and January 31 2010, were included. During this second wave of pandemic influenza A(H1N1)pdm09, all children admitted to PICU with clinical symptoms of H1N1 infection or strong epidemiologic link to patients with known H1N1 infection were tested for H1N1, in both countries. Proven A(H1N1)pdm09 corresponded to World Health Organization criteria in both countries: Any specimen yielding influenza A(H1N1) pdm09 by polymerase chain reaction and/or viral cul ture [20] . Variables in common between both databases were identified.
Data collection and outcomes
The data collected in both cohorts included demographic characteristics, vaccination history, comorbid conditions, admission severity of illness according to the Pediatric Logistic Organ Dysfunction (PELOD) [21] and Pediatric Index of Mortality 2 (PIM2) [22] scores, and intensive care management conditions. The geographic area of 17 Canadian PICUs corresponded to a pediatric popula tion of almost 6 millions children [23] and the 25 French
PICUs cover a pediatric population of almost 11 millions children [24] . We also collected data on infection severity including acute respiratory distress syndrome (ARDS) that is characterized by an acute hypoxemia due to lung inflammation [1] in reaction to viral infection or secondary bacterial infection, nosocomial infection that could result from invasive treatments and seizures. The study's primary objective was to assess whether vaccination prior to hospitalization protects against critical illness. The secondary outcomes were A(H1N1)pdm09 incidence, the timing of the epidemic peak and the epidemic duration, PICU mortality, the incidence and duration of invasive mechanical ventilation, PICU length of stay between the two countries. Mechanical ventila tion was considered invasive if delivered through an endotracheal tube or a tracheostomy. The duration of each episode of mechanical ventilation was defined as the time from intubation to final extubation or death. Mechanical ventilation was considered noninvasive if delivered through a nasal or facemask interface. Total duration of ventilation corresponded to the sum of the periods of both invasive and noninvasive ventilation.
Statistical analysis
Descriptive statistics included counts and proportions, means (and standard deviations), medians (and inter quartile ranges) as appropriate. Incidence and incidence curves were calculated using as a denominator, the number of susceptible patients in the population in each country from Statistics Canada and the "Institut National de la Statistique et des Etudes Economiques" in France. We compared the two countries using bi variate analysis including Pearson's χ 2 test or Fisher's exact test for categorical variables. Student's ttest, Wilcoxon ranksum test or the logrank test, were used for continuous variables. To assess associations between patient or country factors and outcomes, we performed a multivariate logistic regression for invasive ventilation risk and Cox proportional hazards modeling for timedependent variables such as length of stay and invasive ventilation duration. Because data came from two different cohorts, there was heterogeneity in data distributions, requiring countryspecific analyses for many variables. Variables used in final multivariate models met the following criteria: Factors of clinical interest or possibly associated with the outcomes (P < 0.1 in univariate analysis), more than 3 cases per group and per country, and with few (< 5%) missing values in each country. All variables were tested for excessive (> 0.80) colinearity. For Cox regression modeling, variables re spected the proportional hazards assumption. Analyses were considered statistically significant at α < 0.05. SPPS version 19 was used for all analyses. The statistical methods of this study were performed by a biomedical statistician (Thierry Ducruet from SainteJustine Hospital, coauthor).
RESULTS
Epidemiologic data
In total 285 children were included, 160 in Canada and 125 in France. The rate of admission to PICU due to A(H1N1)pdm09, calculated using the estimated pop ulation studied (see methods), was 2.63 per 100000 children in Canada and 1.15 per 100000 children in France ( Table 1 ). The incidence curves showed a higher peak (41 vs 17 admissions per week, both during week 45) but shorter pandemic period (6 wk vs 11 wk) in Canada compared to France (Figure 1 ). (Table 1) The sex ratios and age distribution of critically ill children were similar in Canada and in France. After vaccination program start (Figure 1 ), vaccination coverage prior to hospitalization of children admitted to PICU was higher in Canada than in France (21% vs 2% of children respec tively, P < 0.001), and in both countries, this vaccination coverage was substantially lower than that of the general pediatric population (P < 0.001, using conservative estimates of 54% in children in Canada and 18% in ). Comorbid conditions were common in both Canada and France but individual distributions were different.
Baseline characteristics and health status on admission
Clinical presentation and hospital course
The most common reason for PICU admission was lower respiratory infection in both Canada (63%) and France (72%) and clinical presentations at admission were similar between the two countries ( Table 1 ). The mean organ dysfunction score (PELOD score) at day one and mean predicted mortality score (PIM2 score) were similar. During hospitalization, there was a higher rate of severity of illness in France: ARDS, nosocomial infection, nosocomial pulmonary infection, and seizures (Table 2) .
Outcomes
Mortality rate (4.4% vs 6.5%, P = 0.45) and rate of invasive mechanical ventilation (49% vs 40%, P = 0.14) were similar in Canada and France ( Table 2 ). The dura tion of invasive mechanical ventilation (median, 4 d vs 6 d, P = 0.02) and total (invasive and noninvasive) mechanical ventilation (4 d vs 5 d, P = 0.07) was shorter in Canada than in France ( Table 2 ). The mean PICU length of stay was shorter in Canada (5.7 d vs 8.2 d, P = 0.03) but median PICU length of stay was not different (3 d vs 2.9 d) .
Among Canadian patients, independent multivariate analyses showed that H1N1 vaccination and asthma were associated with an almost fourfold decrease risk of invasive ventilation: (OR = 0.3, 95%CI: 0.110.83, P = 0.02) and (OR = 0.23, 95%CI: 0.090.64, P = 0.004), respectively ( (Table 1) .
DISCUSSION
Key findings
In this binational observational study of pandemic influenza A(H1N1)associated critically illness in children, we found that pandemic influenza A(H1N1) vaccination prior to hospitalization was less common among critically ill children when compared to the general paediatric population, and that history of vaccination was not associated with a clinically relevant difference in PICU length of stay (0.1 d). However, in Canada, with higher vaccine coverage among critically ill patients, the PICU course seems less severe (shorter duration of invasive mechanical ventilation and PICU stay, lesser development of ARDS, and fewer subsequently acquired bacterial infections) ( Table 2) .
Despite a higher vaccine coverage and potential previous exposure to the virus in Canada during the first pandemic wave in the Spring of 2009 [1] , the incidence of admission of critically ill children to intensive care due to Influenza A(H1N1)pdm09 during the Fall of 2009 was twice as high in Canada as in France (2.6 per 100000 children vs 1.1 per 100000 children). However, the mortality rate for these critically ill children was similar between the two countries.
We originally hypothesized that the higher child vaccination coverage in Canada (> 50% vs 18% in France) and previous exposure to influenza A(H1N1) pdm09 would have protected Canadian children from critical illness in the Fall of 2009. We did not observed such a protection. This hypothesis was based on the following arguments: (1) previous exposure to influenza A(H1N1)pdm09 would have increased herd immunity; (2) adjuvant pandemic vaccine has an efficacy up to 97% [2527] ; (3) an influenza vaccination coverage rate above 45% reduces influenza transmission [28] ; and (4) modeling studies suggested that the vaccination campaign was associated with a decrease in mortality and morbidity of 20% and 18% respectively [29] . Other factors previously identified as contributing to outbreak Table 3 Critically ill patient-based factors associated with risk of invasive ventilation in Canada spread such as proximity to the first infectious focus, human mobility, reproduction number, generation time, population susceptibility, age pyramid, school calendar, and climate [30] were similar between the two countries and the underlying characteristics of the children were similar ( Table 1 ). Given that the difference in incidence of PICU admission was the opposite of what was expected, our study suggests that additional national, geography specific, and/or further unappreciated factors likely exhibit substantial residual influence on the incidence of pandemic influenza in differing regions of the world. It has also been shown that the virulence of influenza A(H1N1)pdm09 strains virulence can vary considerably in animals and in humans [3135] . Some specific strains were associated with severe disease in Canada and France but the proportion of these virulent strains in Canada and France is incompletely reported. Differing virulence could have contributed to the increased incidence of critical illness in Canada, as well as to the higher mortality observed in Argentina and Turkish pediatric cohorts when compared with those in North America, Europe and Australia and New Zealand [3639] . Despite the higher incidence of critical illness in Canada when compared to France, our study provides some arguments on the positive impact of vaccine on influenza critical illness in children, even when the vaccine is given when pandemic second wave has already started ( Figure 1 ). Our study showed that: (1) the second wave ended earlier than in France, which had a lower vaccine coverage; (2) vaccination coverage was substantially lower in the PICU population than in the general pediatric population; (3) total duration of mechanical ventilation was shorter in Canada; and (4) vaccination was associated with a decreased risk of invasive mechanical ventilation ( Table 3) . As expected, asthma was also associated with a decreased risk of invasive ventilation. This is consistent with previous findings of a low rate (4.6%) of invasive mechanical ventilation in PICU patients admitted for acute asthma [40] . The significant association between vaccination coverage and reduction in invasive mechanical ventilation is remarkable considering that the rate of invasive mech anical ventilation in children without a diagnosis of asthma diagnosis in this study was > 40%.
Strengths and weaknesses of the study
This study has several strengths: (1) It represents the largest pediatric cohort of critically ill H1N1 infection yet described in Canada and France; (2) the evolution of new H1N1 cases per week in PICUs (Figure 1 ) was similar to the consultations rates for influenza like illness in the general population of Canada and France [41, 42] ; and (3) there was a large difference in vaccine coverage. This difference in coverage may be attributed to differences in perception of risk amongst the population such as awareness of the public health issues, the risk of being infected by the virus, the risk of severe illness if infected, and the risk of harm from a pandemic vaccine [43, 44] .
Our study has several limitations that should be noted. First, the suspected difference in virulence be tween the two countries could have created a bias on the analysis of pandemic vaccine impact. However, the analysis of critically ill children in Canada only provided an association between vaccine delivery and reduction in the risk of invasive ventilation (Table 3) ; second, admission criteria in PICUs are not standardized across countries and this can impact the incidence of PICU admission and inferred critical illness. However, several arguments suggest that admission criteria between Canada and France are similar, including: (1) the similar number of PICU beds per capita; and (2) patients displayed similar organ failure score (PELOD score) and predicted risk of mortality (PIM2) on admission to PICU (Table 1) . Interestingly, this difference in ICU admission rate was also observed in adult intensive care units, with a rate of A(H1N1)pdm09associated admission of 3.5/100000 population in Canada and 2.1/100000 population in France (OR = 1.7) [45, 46] . Another limitation is that the two national cohorts used similar but not identical case report forms. Therefore, we needed to compare similar variables that may have been collected in slightly different ways in order to compare the two cohorts. In order to address this point for future outbreaks and pandemics, a number of national critical care research consortia initiated the International Forum of Acute Care Trialists which seeks to improve the care of acutely ill patients around the world by harmonizing case report forms and definitions [47] . This goal has been further advanced by the creation of International Severe Acute Respiratory and Emerging Infection Consortium.
In conclusion, the critical illness due to H1N1pdm09 had a higher incidence in Canada than in France. In both Canada and France, critically ill children were much less likely to have received vaccination against influenza A(H1N1)pdm09 prior to hospitalization when compared with children in the general population. In Canada, with higher vaccine coverage among critically ill patients, the PICU course seems less severe and the risk of invasive mechanical ventilation was lower amongst Canadian critically ill children receiving prior vaccination. There is a need for further studies to confirm our observations as numerous and still uncertain factors influence diffe rences in pandemic influenza incidence and severity in different regions of the world, even in countries with similar population characteristics, access to health care resources and response systems.
